ESC Premium Access

Reduced stroke risk without increased bleeding risk in patients with atrial fibrillation and complicated liver cirrhosis treated with oral anticoagulation

Congress Presentation

About the speaker

Doctor Kamilla Steensig

Aalborg University Hospital, Aalborg (Denmark)
0 follower

7 more presentations in this session

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with antiphospholipid syndrome: a nationwide cohort study

Speaker: Assistant Professor P. Yang (Seongnam, KR)

Thumbnail

Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study

Speaker: Doctor M. Proietti (Milan, IT)

Thumbnail

Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48

Speaker: Professor J. Steffel (Zurich, CH)

Thumbnail

Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS)

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Access the full session

Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation in ‘Special’ Situations

Speakers: Doctor K. Steensig, Assistant Professor P. Yang, Doctor M. Proietti, Doctor T. Chao, Professor J. Steffel...
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations